June 06, 2023
Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations
June 01, 2023
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
May 31, 2023
Alkermes to Participate in Two Upcoming Investor Conferences
Hear from Steve Schiavo on Alkermes' commitment to being a recovery-friendly workplace.
We’re proud to recognize Swetha Krishnan, Senior Director of Quality, as our 2023 Healthcare Businesswomen’s Association (HBA) Rising Star – a testament to her leadership and commitment to excellence.
Hear from Markus Haeberlein, Ph.D. where he discusses our commitment to researching potential treatment options for people living with sleep disorders.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.